Current CKD therapies, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, and anti-inflammatory agents, focus on controlling comorbid conditions, such as hypertension, cardiovascular disease, and diabetes. This evidence concerns the gene ACE and cardiovascular disorder.